Sign in Subscribe

PharmGKB Staff

(Untitled)

We have updated the pathway: Tamoxifen PK pathway. Tamoxifen is a selective estrogen receptor modulator. It is used to treat estrogen receptor positive breast cancer, and has been shown to decrease disease recurrence and mortality rates by 50% and 30%, respectively. PharmGKB's Tamoxifen PK pathway describes the metabolism

Personalized Medicine World Conference 2013

PharmGKB curators attended the PMWC this week, featuring talks covering different areas and aspects of personalized medicine, including pharmacogenetics, co-drug and diagnostics development, adaptation of clinical trials, systems medicine, wellness, sequencing technologies, and implementation.

CPIC guidelines for TPMT and Thiopurine dosing: Update 2013

The 2013 update of the CPIC guidelines for TPMT and Thiopurine dosing is now available online, as an accepted article preview. CPIC genotype-based dosing guidelines are reviewed and updated every two years in order to be clinically current - this is the first update to be released. After an extensive

Additional EMA drug labels released on PharmGKB

Our collection of drug labels containing pgx information from the European Medicines Agency has been extended: Boceprevir and IL28 Brentuximab vedotin and CD30 (TNFRSF8) Capecitabine and DYPD Cetuximab and KRAS Crizotinib and ALK Dasatinib and the Philadelphia chromosome Eltrombopag and F5, SERPINC1 Everolimus and ERBB2 (HER2) Fulvestrant and estrogen receptor

Tailored therapy in asthma? ADRB2 genotype in the context of salmeterol therapy

In a recent trial, asthmatic children homozygous for the beta2-adrenergic receptor Arg16 variant (ADRB2 gene, rs1042713 genotype AA) were randomized and treated with either salmeterol (a beta2-adrenergic receptor agonist) or montelukast (a leukotriene receptor antagonist), both combined with fluticasone. Those in the montelukast treatment group displayed significantly better responses in

CP&T Issue Focuses on Personalized Medicine

The October 2012 issue of Clinical Pharmacology & Therapeutics focuses on individualized medicine including articles that discuss, reveal and tackle key issues in the field of PGx, and provides examples of current clinical implementation projects. Clinical Pharmacology & Therapeutics Volume 92, Issue 4 (October 2012) Amongst these are articles by

European Medicines Agency Drug Labels

European Public Assessment Reports (EPARs) for drugs published by the European Medicines Agency (EMA) that include pgx information are now available to view on PharmGKB. We add any pgx-containing EMA or FDA drug labels that come to our attention. Like our FDA drug label information, we provide a summary and

From Genomics & Informatics to Precision Medicine

Several PharmGKB curators plan to attend UCSF's Institute for Human Genetics 2012 Symposium on Monday 5th Nov, entitled "From Genomics and Informatics to Precision Medicine". Speakers include those from Genentech, Kaiser Permanente and prominent universities in the USA. We hope to see you there!

PharmGKB team celebrates Halloween

The PharmGKB team joined the Halloween celebrations this week - take a look at our pumpkin carving skills!

ASHG Annual Meeting 2012 (6th-10th Nov)

The PharmGKB curators will be attending the American Society of Human Genetics Annual Meeting in San Francisco next week and look forward to a week of interesting talks and posters. On Thursday 8th November (2:15-3:15pm) we will be presenting two posters - one focusing on the pharmacogenomic research